PolyPid Ltd..
PYPD.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
PolyPid Ltd. is a biopharmaceutical company focused on developing and commercializing pharmaceutical products using its proprietary PLEX (Polymer-Lipid Encapsulation Matrix) technology. This technology allows for targeted and controlled drug delivery over extended periods. The company's lead product...Show More
Better Health for All
10
PolyPid Ltd. is a biopharmaceutical company focused on developing and commercializing pharmaceutical products, with its lead product candidate, D-PLEX100, designed for the prevention of surgical site infections (SSIs). The company's stated focus is on improving patient outcomes. Positive topline results from the SHIELD-II trial for D-PLEX100 indicate that this product delivers significant health benefits.
1
The positive topline results from the SHIELD-II trial also suggest strong ethical conduct in the clinical trial process.
Fair Money & Economic Opportunity
0
No evidence available to assess PolyPid Ltd. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No evidence available to assess PolyPid Ltd. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No specific, concrete data points related to fair trade or ethical sourcing practices, such as fair-trade certification share, audit frequency, forced/child labor incidents, traceability coverage, remediation speed, ethical clause coverage, materials risk index, or supplier diversity spend, were found in the provided articles.
1
The articles explicitly state a lack of relevant data or were inaccessible.
2
Honest & Fair Business
-40
PolyPid Ltd. has a Whistleblower Policy available on its corporate website, and its Audit Committee is responsible for establishing procedures for the confidential, anonymous submission of concerns regarding accounting or auditing matters, including protection for complaining employees.
1
However, there is no explicit evidence of independent investigation processes.
2
The Audit Committee Charter, effective 2020, requires members to be independent as per applicable law and Nasdaq Rules, and at least one member must be an “audit committee financial expert.”
3
The Audit Committee reviews related party transactions and potential conflicts of interest.
4
The company has a Corporate Code of Ethics and Conduct and an Anti-Corruption Policy available on its corporate website.
5
The Audit Committee monitors the implementation of the Code of Ethics, but there is no information on the frequency or effectiveness of anti-corruption training.
6
Kind to Animals
0
The provided articles confirm that PolyPid Ltd. utilizes animal models in its preclinical studies for drug development. Specifically, the OncoPLEX intra-tumoral cancer therapy program has been evaluated in various animal tumor models, including colon carcinoma, melanoma, and glioblastoma.
1
Additionally, preclinical data for D-PLEX100's safety profile involved administering the product to juvenile swine.
2
However, the articles do not provide any quantitative data regarding the number of animals used annually, the percentage of R&D budget invested in animal-free alternatives, or any information on animal welfare policies, certifications, or conservation efforts.
No War, No Weapons
0
PolyPid Ltd. is a biopharmaceutical company focused on developing pharmaceutical products, specifically an antibiotic for surgical site infections.
1
The provided articles detail financial results, clinical trial progress for D-PLEX100, and regulatory submission plans. There is no evidence in the articles to suggest any involvement in arms manufacturing, military contracts, dual-use technologies, sales to embargoed regimes, or any other activities related to the 'No War, No Weapons' value. The company's core business, as described and evidenced, is entirely civilian and medical in nature.
Planet-Friendly Business
0
No evidence available to assess PolyPid Ltd. on Planet-Friendly Business.
Respect for Cultures & Communities
0
No evidence was found in the provided articles regarding PolyPid Ltd.'s performance on any of the KPIs related to Respect for Cultures & Communities. The articles primarily focus on clinical trial results, regulatory designations, and company financing, without addressing community engagement, cultural impact, or related social responsibility metrics.
1
Safe & Smart Tech
0
The company's privacy and security policies, updated in November 2021
1
and December 2020 respectively,
2
outline standard practices for data protection. Data is retained only as necessary and in accordance with applicable laws.
3
Users are granted rights to access, amend, object to, port, and delete their data, and can withdraw consent.
4
The company states compliance with GDPR, CCPA, and HIPAA.
5
Security measures include encryption for data transfer (e.g., L2TP, IPsec) and stored data, password policies, lockout mechanisms, automatic session termination, access controls, logging, and monitoring to prevent unauthorized data use.
6
Security measures are also integrated throughout the product development lifecycle.
7
Zero Waste & Sustainable Products
0
No evidence available to assess PolyPid Ltd. on Zero Waste & Sustainable Products.